Bullous Wells Syndrome Responsive to Low-Dose Dapsone: A Case Report

Ralfi Singer *

Department of Dermatology, Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, 34384, Turkey.

Ömer Özdemir

Department of Dermatology, Siirt Training and Research Hospital, Siirt, 56000, Turkey.

Selver Özekinci

Department of Pathology, Dicle University Hospital, Diyarbakır, 21280, Turkey.

*Author to whom correspondence should be addressed.


Abstract

Wells’ syndrome (WS) is an uncommon inflammatory dermatosis of unknown etiology which typically presents with pruritic cellulitis-like plaques on the extremities. The condition is thought to be a hypersensitivity reaction developing against a variety of exogenous and endogenous antigenic stimuli. Although the classic plaque type variant is the most common presentation, bullous, papulonodular, papulovesicular, granuloma-like, urticarial-like and fixed drug eruption types may be encountered as well. Histopathology is characterised by tissue eosinophilia, edema and flame figures. Treatment options include topical and systemic corticosteroids, topical calcineurin inhibitors, doxycycline, cetirizine, cyclosporine, tumor necrosis factor-α inhibitors and psoralen and long-wave ultraviolet light (PUVA). Here, we present a case of bullous WS responding to low-dose dapsone treatment

Keywords: Eosinophilic cellulitis, wells syndrome, bullous wells syndrome, dapsone


How to Cite

Singer , Ralfi, Ömer Özdemir, and Selver Özekinci. 2023. “Bullous Wells Syndrome Responsive to Low-Dose Dapsone: A Case Report”. Asian Journal of Research in Dermatological Science 6 (1):48-52. https://journalajrdes.com/index.php/AJRDES/article/view/85.

Downloads

Download data is not yet available.

References

Heelan K, Ryan JF, Shear NH, Egan CA. Wells syndrome (eosinophilic cellulitis): Proposed diagnostic criteria and a literature review of the drug-induced variant. J Dermatol Case Rep. 2013;7: 113-120.

Räßler F, Lukács J, Elsner P. Treatment of eosinophilic cellulitis (Wells syndrome) – a systematic review. J Eur Acad Dermatol Venereol. 2016;30:1465-1479.

Bokotas C, Kouris A, Stefanaki C, Sgotzou T, Christofidou E, Kontochristopoulos G. Wells syndrome: Response to dapsone therapy. Ann Dermatol. 2014;26:541–542.

Plötz SG, Abeck D, Behrendt H, Simon HU, Ring J. Eosinophilic cellulitis (wells syndrome). Hautarzt. 2000;51:182-186.

Lim CE, Ng SK, Thng ST. Bullous pesentation of ıdiopathic wells syndrome (Eosinophilic cellulitis). Ann Acad Med Singapore. 2017;46:324-326.

Fujimoto N1, Wakabayashi M, Kato T, Nishio C, Tanaka T. Wells syndrome associated with churg-strauss syndrome. Clin Exp Dermatol. 2011;36:46-48.

Coelho de Sousa V, Laureano Oliveira A, Cardoso J. Successful treatment of eosinophilic -cellulitis with dapsone. Dermatol Online Journal. 2016;22(7): 13030/qt9v67b10b.

Spinelli M, Frigerio E, Cozzi A, Garutti C, Garavaglia MC, Altomare G. Bullous Wells' syndrome associated with non-Hodgkin's lymphocytic lymphoma. Acta Derm Venereol. 2008;88:530-531.

Egeland Ø, Balieva F, Undersrud E: Wells syndrome: A case of successful treatment with omalizumab. International Journal of Dermatology. 2018;57:994–995.

Bozeman PM, Learn DB, Thomas EL. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol. 1992;44:553-563.